DK3934637T3 - (n-)acetyl-l-leucin til anvendelse til behandling af traumatisk hjerneskade - Google Patents

(n-)acetyl-l-leucin til anvendelse til behandling af traumatisk hjerneskade Download PDF

Info

Publication number
DK3934637T3
DK3934637T3 DK20712029.6T DK20712029T DK3934637T3 DK 3934637 T3 DK3934637 T3 DK 3934637T3 DK 20712029 T DK20712029 T DK 20712029T DK 3934637 T3 DK3934637 T3 DK 3934637T3
Authority
DK
Denmark
Prior art keywords
leucine
acetyl
treatment
brain injury
traumatic brain
Prior art date
Application number
DK20712029.6T
Other languages
Danish (da)
English (en)
Inventor
Mallory Factor
Taylor Fields
Original Assignee
Intrabio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intrabio Ltd filed Critical Intrabio Ltd
Application granted granted Critical
Publication of DK3934637T3 publication Critical patent/DK3934637T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK20712029.6T 2019-03-02 2020-03-02 (n-)acetyl-l-leucin til anvendelse til behandling af traumatisk hjerneskade DK3934637T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962812987P 2019-03-02 2019-03-02
US201962842296P 2019-05-02 2019-05-02
US201962888894P 2019-08-19 2019-08-19
US201962895144P 2019-09-03 2019-09-03
PCT/IB2020/051767 WO2020178721A1 (en) 2019-03-02 2020-03-02 Leucine, acetyl leucine, and related analogs for treating disease

Publications (1)

Publication Number Publication Date
DK3934637T3 true DK3934637T3 (da) 2024-09-02

Family

ID=69845470

Family Applications (1)

Application Number Title Priority Date Filing Date
DK20712029.6T DK3934637T3 (da) 2019-03-02 2020-03-02 (n-)acetyl-l-leucin til anvendelse til behandling af traumatisk hjerneskade

Country Status (25)

Country Link
US (1) US20220142959A1 (cg-RX-API-DMAC10.html)
EP (2) EP4464378A3 (cg-RX-API-DMAC10.html)
JP (2) JP7555346B2 (cg-RX-API-DMAC10.html)
KR (2) KR102941068B1 (cg-RX-API-DMAC10.html)
CN (2) CN119097618A (cg-RX-API-DMAC10.html)
AU (2) AU2020231189B2 (cg-RX-API-DMAC10.html)
BR (1) BR112021017203A2 (cg-RX-API-DMAC10.html)
CA (1) CA3131948A1 (cg-RX-API-DMAC10.html)
DK (1) DK3934637T3 (cg-RX-API-DMAC10.html)
ES (1) ES2990183T3 (cg-RX-API-DMAC10.html)
FI (1) FI3934637T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20241150T1 (cg-RX-API-DMAC10.html)
HU (1) HUE068527T2 (cg-RX-API-DMAC10.html)
IL (2) IL321899A (cg-RX-API-DMAC10.html)
LT (1) LT3934637T (cg-RX-API-DMAC10.html)
MA (1) MA55199B1 (cg-RX-API-DMAC10.html)
MD (1) MD3934637T2 (cg-RX-API-DMAC10.html)
MX (2) MX2021010568A (cg-RX-API-DMAC10.html)
PL (1) PL3934637T3 (cg-RX-API-DMAC10.html)
PT (1) PT3934637T (cg-RX-API-DMAC10.html)
RS (1) RS65849B1 (cg-RX-API-DMAC10.html)
SG (1) SG11202109512SA (cg-RX-API-DMAC10.html)
SI (1) SI3934637T1 (cg-RX-API-DMAC10.html)
SM (1) SMT202400334T1 (cg-RX-API-DMAC10.html)
WO (1) WO2020178721A1 (cg-RX-API-DMAC10.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201709459D0 (en) 2017-06-14 2017-07-26 Intrabio Ltd Treatment for migraine
CN120157593A (zh) 2018-12-06 2025-06-17 内在生物技术有限公司 乙酰基-亮氨酸的氘代类似物
MD3989962T2 (ro) 2019-06-28 2025-12-31 Intrabio Ltd Gb Terapie combinată cu acetil-leucină și miglustat pentru tratamentul unei boli de depozitare lizozomală
WO2021144720A1 (en) 2020-01-13 2021-07-22 Intrabio Ltd Treatment of late-onset neurodegenerative diseases in heterozygous npc1 gene mutation carriers
WO2022125304A1 (en) * 2020-12-10 2022-06-16 Texas Tech University System Bcaa-lowering compounds for prevention and/or treatment of alzheimer's disease and related disorders
WO2022264037A1 (en) * 2021-06-14 2022-12-22 Intrabio Ltd. Branched-chain amino acid derivatives to treat disease
WO2024243004A2 (en) * 2023-05-19 2024-11-28 The Children's Hospital Of Philadelphia Compositions and methods for treating traumatic brain injury
WO2025166100A1 (en) * 2024-02-02 2025-08-07 SynGAP Research Fund Compositions and methods for treating neurodevelopmental disorders
WO2025175092A1 (en) * 2024-02-14 2025-08-21 Intrabio Inc. Acetyl leucine for treating syngap1-related disorders
TW202604470A (zh) * 2024-06-20 2026-02-01 美商音特拉拜歐公司 乙醯白胺酸用於治療神經發育障礙

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060063827A1 (en) * 2004-09-23 2006-03-23 Yu Ruey J Systemic administration of therapeutic amino acids and N-acetylamino acids
FR2905600B1 (fr) * 2006-09-13 2010-01-15 Pf Medicament Traitement des vertiges par l'acetyl-l-leucine.
TN2010000251A1 (fr) * 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
CA2803166C (en) 2010-06-25 2023-03-07 Shire Human Genetic Therapies, Inc. Cns delivery of therapeutic agents
US20140080885A1 (en) * 2012-09-13 2014-03-20 University Of South Florida (A Florida Non-Profit Corporation) Methods of treating traumatic brain injury
PT3445351T (pt) * 2016-04-19 2024-11-14 Intrabio Ltd Acetil-leucina ou um sal farmaceuticamente aceitável seu derivado para melhoria da mobilidade
TN2016000259A1 (en) * 2016-06-27 2017-10-06 Rekik Raouf Salbutamol (albuterol) eye protective medicament.
PT3482754T (pt) 2016-08-11 2021-02-03 Intrabio Ltd Composições farmacêuticas e utilizações contra os distúrbios de armazenamento lisossómico
TN2019000033A1 (fr) * 2016-08-11 2020-07-15 Intrabio Ltd Agents thérapeutiques pour maladies neurodégénératives
US20190046486A1 (en) * 2017-08-14 2019-02-14 Axcella Health Inc. Compositions and methods for the treatment of neuronal injury

Also Published As

Publication number Publication date
CA3131948A1 (en) 2020-09-10
EP3934637A1 (en) 2022-01-12
RS65849B1 (sr) 2024-09-30
SMT202400334T1 (it) 2024-09-16
HRP20241150T1 (hr) 2024-11-22
AU2020231189A1 (en) 2021-09-30
MA55199A (fr) 2022-01-12
AU2025204995A1 (en) 2025-07-17
EP4464378A3 (en) 2025-04-09
EP3934637B1 (en) 2024-07-31
CN114040757B (zh) 2024-09-20
KR102941068B1 (ko) 2026-03-18
MA55199B1 (fr) 2024-08-30
MD3934637T2 (ro) 2024-12-31
JP2024170602A (ja) 2024-12-10
PT3934637T (pt) 2024-08-30
WO2020178721A1 (en) 2020-09-10
IL285870B1 (en) 2025-08-01
BR112021017203A2 (pt) 2021-12-14
CN119097618A (zh) 2024-12-10
CN114040757A (zh) 2022-02-11
PL3934637T3 (pl) 2024-10-14
JP7555346B2 (ja) 2024-09-24
IL321899A (en) 2025-09-01
FI3934637T3 (fi) 2024-09-02
US20220142959A1 (en) 2022-05-12
EP4464378A2 (en) 2024-11-20
IL285870A (en) 2021-10-31
MX2024015063A (es) 2025-01-09
LT3934637T (lt) 2024-08-26
JP2022522819A (ja) 2022-04-20
MX2021010568A (es) 2021-11-12
ES2990183T3 (es) 2024-11-29
AU2020231189B2 (en) 2025-07-24
KR20250171484A (ko) 2025-12-08
HUE068527T2 (hu) 2025-01-28
IL285870B2 (en) 2025-12-01
SG11202109512SA (en) 2021-09-29
KR20210135272A (ko) 2021-11-12
SI3934637T1 (sl) 2024-10-30

Similar Documents

Publication Publication Date Title
DK3743053T3 (da) Anvendelse af cannabinoider i behandling af epilepsi
EP3538548A4 (en) IL-2 VARIANTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
DK3673080T3 (da) Antisense-oligomerer til behandling af lidelser og sygdomme
DK4028010T3 (da) Vs-6063 i kombination med ch5126766 til behandlingen af kræft
EP3568129A4 (en) GLYCERYL 3-HYDROXYBUTYRATES FOR TRAUMATIC BRAIN DAMAGE
IL256166B (en) Compounds for use in treating neuromuscular disorders
DK3429571T3 (da) Kombinationer af lsd1-hæmmere til anvendelse til behandling af neoplastiske sygdomme
DK3334422T3 (da) Anvendelse af cannabidiolsyre i behandling af epilepsi
DK3882250T3 (da) Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser
DK3504187T3 (da) Anvendelse af pridopidin til behandling af funktionel tilbagegang
DK3806898T3 (da) Gremlin-1-antagonist til anvendelse i behandling af cancer
DK3865484T3 (da) Pde9-hæmmer med imidazopyrazinon-rygrad til behandling af perifere sygdomme
EP3397261C0 (en) SUB-MITOCHONDRIAL PARTICLES FOR USE IN THE TREATMENT OF CARDIOVASCULAR DISEASES
DK3328864T3 (da) Terapeutiske forbindelser og sammensætninger til behandling af sociale forstyrrelser og stofmisbrugsforstyrrelser
IL282311A (en) Use of reboxetine to treat narcolepsy
PL3934637T3 (pl) (n-)acetylo-l-leucyna do stosowania w leczeniu urazowego uszkodzenia mózgu
DK3710000T3 (da) Tradipitant til anvendelse til behandling af gastroparese
EP3496733C0 (en) COMPOSITION FOR USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER
DK3191103T3 (da) Sammensætninger og fremgangsmåder til behandling af præcancerøse hudlæsioner
DK3522873T3 (da) Sammensætninger og fremgangsmåder til behandlingen af xerostomi
DK3592355T3 (da) KX2-391/KX-01 til anvendelse i behandling af aktinisk keratose
IT201600121601A1 (it) Composizione orale per il trattamento del reflusso gastroesofageo e del reflusso laringo-faringeo
IL289371A (en) Methylthioninium for use in the treatment of synaptopathies
IL282041A (en) Egfr inhibitors for treating keratodermas
DK3302573T3 (da) Sammensætning til behandlingen af hjernelæsioner